Improving therapies for a range of human genetic diseases focusing on lysosomal storage diseases
Amicus (NASDAQ: FOLD) is focused on the discovery and development of therapeutics for rare and orphan diseases. The company's pipeline is based on its pharmaceutical chaperone technology to stabilize mutated proteins that are unstable, misfolded, or unfolded. Amicus completed its IPO on NASDAQ in 2007.
